Immunosuppressants - Mozambique

Mozambique

The Immunosuppressants market in Mozambique is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is set to reach US$4.83m in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 17.18% from 2024 to 2029, resulting in a market volume of US$10.67m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Immunosuppressants market, reaching a staggering US$35,470.00m in 2024.
In Mozambique, the demand for immunosuppressants is increasing due to the rising prevalence of autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Mozambique has been on the rise in recent years.

Customer preferences: Patients in Mozambique suffering from autoimmune diseases such as lupus, rheumatoid arthritis, and psoriasis are the main consumers of immunosuppressants. These patients require long-term medication to manage their conditions. Due to the lack of access to advanced medical facilities in the country, immunosuppressants are often the only option for these patients.

Trends in the market: The immunosuppressants market in Mozambique has been growing steadily due to an increase in the prevalence of autoimmune diseases in the country. The market is dominated by generic drugs, which are more affordable for patients. The market has also seen the entry of new players in recent years, leading to increased competition.

Local special circumstances: Mozambique has a weak healthcare system, which has led to a lack of access to advanced medical facilities and a shortage of medical personnel. This has resulted in a high demand for immunosuppressants as they are often the only option for patients. The country also has a high prevalence of HIV/AIDS, which increases the risk of developing autoimmune diseases.

Underlying macroeconomic factors: Mozambique is a low-income country with a GDP per capita of less than $500. The country has been experiencing economic growth in recent years, but this growth has been unevenly distributed, with a large portion of the population still living in poverty. This has led to a lack of access to healthcare for many Mozambicans, which has contributed to the high demand for immunosuppressants. The government has been working to improve healthcare infrastructure in the country, but progress has been slow due to limited resources.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.